Compare · LSTA vs VMD
LSTA vs VMD
Side-by-side comparison of Lisata Therapeutics Inc. (LSTA) and Viemed Healthcare Inc. (VMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LSTA and VMD operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- VMD is the larger of the two at $346.6M, about 22.1x LSTA ($15.7M).
- VMD has been more active in the news (10 items in the past 4 weeks vs 3 for LSTA).
- VMD has more recent analyst coverage (2 ratings vs 0 for LSTA).
- Company
- Lisata Therapeutics Inc.
- Viemed Healthcare Inc.
- Price
- -
- -
- Market cap
- $15.7M
- $346.6M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 3
- 10
- Recent ratings
- 0
- 2
Viemed Healthcare Inc.
Viemed Healthcare, Inc., through its subsidiaries, provides in-home durable medical equipment and post-acute respiratory healthcare services to patients in the United States. The company offers respiratory services and related equipment, including non-invasive ventilators; bi-level, continuous, and automatic continuous positive airway pressure (PAP) machines; and oxygen therapy, as well as services of respiratory therapists; and respiratory disease management, neuromuscular care, and oxygen therapy services. It also provides in-home sleep apnea testing services to determine the existence of sleep apnea at home. In addition, the company leases non-invasive and invasive ventilators, PAP machines, percussion vests, oxygen concentrator units, and other respiratory equipment, as well as sells medical equipment and/or patient medical services. Further, it provides therapy and counseling to patients in their homes using its technology. The company was founded in 2006 and is headquartered in Lafayette, Louisiana.
Latest LSTA
- SEC Form 10-Q filed by Lisata Therapeutics Inc.
- Lisata Therapeutics Provides Update Following Termination of Merger Agreement
- Lisata Therapeutics Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Leadership Update, Other Events
- Lisata Therapeutics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Other Events
- Amendment: SEC Form SC 14D9/A filed by Lisata Therapeutics Inc.
- Lisata Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
- Amendment: SEC Form SC 14D9/A filed by Lisata Therapeutics Inc.
- Amendment: SEC Form SC 14D9/A filed by Lisata Therapeutics Inc.
- Amendment: SEC Form SC 14D9/A filed by Lisata Therapeutics Inc.
- SEC Form SC 14D9 filed by Lisata Therapeutics Inc.
Latest VMD
- Barrington Research initiated coverage on Viemed Healthcare with a new price target
- Viemed Healthcare Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Director Heltz Sabrina converted options into 18,786 shares and returned $33,588 worth of shares to the company (3,757 units at $8.94), increasing direct ownership by 22% to 82,520 units (SEC Form 4)
- Director Dobbs Randy E. converted options into 20,954 shares and returned $37,468 worth of shares to the company (4,191 units at $8.94), increasing direct ownership by 13% to 142,253 units (SEC Form 4)
- Director Kaushal Nitin converted options into 18,786 shares, increasing direct ownership by 13% to 161,361 units (SEC Form 4)
- Director Smokoff Timothy converted options into 18,786 shares and returned $33,588 worth of shares to the company (3,757 units at $8.94), increasing direct ownership by 20% to 90,547 units (SEC Form 4)
- SEC Form S-8 filed by Viemed Healthcare Inc.
- SEC Form 10-Q filed by Viemed Healthcare Inc.
- Viemed Healthcare Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Viemed Healthcare Announces Second Quarter 2026 Financial Results